Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
| Revenue (TTM) | $6.01B |
| Gross Profit (TTM) | $3.37B |
| EBITDA | $2.04B |
| Operating Margin | 33.70% |
| Return on Equity | 7.84% |
| Return on Assets | 17.80% |
| Revenue/Share (TTM) | $30.04 |
| Book Value | $27.66 |
| Price-to-Book | 4.26 |
| Price-to-Sales (TTM) | 4.06 |
| EV/Revenue | 3.366 |
| EV/EBITDA | 22.55 |
| Quarterly Earnings Growth (YoY) | 37.70% |
| Quarterly Revenue Growth (YoY) | 14.00% |
| Shares Outstanding | $203.83M |
| Float | $171.56M |
| % Insiders | 1.83% |
| % Institutions | 103.91% |
Volatility is currently expanding
I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net sales rose 14% year-over-year; Opzelura and hematology/oncology guidance increased, while Jakafi guidance remains unchanged.
Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript
Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncology products, and total net sales while outlining progress across several late-stage pipeline programs.
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KRAS G12D-targeted small molecule known as “'734.”
INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on INCY and any ticker you trade — then tracks every position and per-strategy win rate.
